ArticleCancer research communications2026
Patient-Level KRAS G12C Prevalence among Hispanic/Latino and Non-Hispanic White Patients in Real-world Clinicogenomic Cohorts.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
KRAS G12C is a treatment-defining biomarker in non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma. Hispanic/Latino (H/L) patients remain undercharacterized in precision oncology datasets, and patient-level KRAS G12C prevalence has not been consistently quantified using strict ethnicity definitions. We analyzed MSK-CHORD as the initial reference cohort and American Association for Cancer Research (AACR) GENIE after excluding the Memorial Sloan Kattering Cancer Center contributing center. H/L required explicit H/L-origin annotation; non-Hispanic White (NH-W) required White race with explicit non-Hispanic ethnicity. Primary analyses compared patient-level KRAS G12C prevalence in mutually exclusive lung adenocarcinoma and non-lung adenocarcinoma NSCLC. In lung adenocarcinoma, KRAS G12C prevalence was lower in H/L than NH-W patients in MSK-CHORD [7.9% vs. 15.4%; odds ratio (OR), 0.47; 95% confidence interval (CI), 0.30-0.74; P < 0.001] and GENIE (7.2% vs. 15.1%; OR, 0.44; 95% CI, 0.33-0.58; P < 0.0001). In non-lung adenocarcinoma NSCLC, differences were smaller and not significant in MSK-CHORD (4.8% vs. 5.1%; OR, 0.94; P = 1) or GENIE (4.9% vs. 6.7%; OR, 0.73; P = 0.461). In MSK-CHORD lung adenocarcinoma, adjustment for smoking shifted the OR from 0.50 to 0.68. H/L patients had lower patient-level KRAS G12C prevalence than NH-W patients with lung adenocarcinoma across two real-world clinicogenomic cohorts. The finding was histology specific and attenuated after smoking adjustment, supporting a biomarker-yield interpretation. SIGNIFICANCE: H/L patients remain undercharacterized in real-world precision oncology datasets. This study provides patient-level, histology-specific estimates of KRAS G12C prevalence among H/L and NH-W patients using strict race/ethnicity definitions, coverage-aware denominators, and two large clinicogenomic cohorts. These findings inform biomarker screening yield in lung adenocarcinoma and support more rigorous, population-aware evaluation of actionable alterations in real-world oncology datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.